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Crystal Structure of PMM/PGM:
An Enzyme in the Biosynthetic Pathway
of P. aeruginosa Virulence Factors
still the most common cause of morbidity and mortality
in CF patients [3].
Several factors affecting the virulence of P. aerugi-
nosa infections have been identified, including exopoly-
saccharides such as alginate [3] and LPS [2]. One of the
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Columbia, Missouri 65211 hallmarks of chronic P. aeruginosa infections in the CF
lung is the conversion of the bacterium to a mucoidy
(alginate-producing) phenotype [3]. Alginate is a re-
peating polymer of -D-mannuronate and -L-guluro-Summary
nate residues and is secreted by the bacteria in re-
sponse to environmental stress (dehydration, nitrogenThe enzyme phosphomannomutase/phosphogluco-
starvation, etc.) and during the formation of bacterialmutase (PMM/PGM) from P. aeruginosa is required for
biofilms [4]. The viscous alginate coating is believed tothe biosynthesis of two bacterial exopolysaccharides:
play a role in the organism’s resistance to antibioticsalginate and lipopolysaccharide (LPS). Both of these
and also to reduce the effectiveness of the host immunemolecules play a role in the virulence of P. aeruginosa,
system. Alginate is present in sputum samples of CFan important human pathogen known for its ability to
patients and antibodies to alginate are present in all CFdevelop antibiotic resistance and cause chronic lung
patients with chronic P. aeruginosa infections [3].infections in cystic fibrosis patients. The crystal struc-
Changes in LPS phenotype are also associated withture of PMM/PGM shows that the enzyme has four
the development of chronic P. aeruginosa infections [2].domains, three of which have a similar three-dimen-
LPS is a complex glycolipid found in the outer membranesional fold. Residues from all four domains of the pro-
of Gram-negative bacteria. It has a tripartite structuretein contribute to the formation of a large active site
consisting of a hydrophobic lipid-containing region thatcleft in the center of the molecule. Detailed information
is part of the bacterial membrane, central core polysac-on the active site of PMM/PGM lays the foundation for
charides, and repeating O-antigen polysaccharidestructure-based inhibitor design. Inhibitors of suffi-
chains that extend out from the surface of the cell. Incient potency and specificity should impair the biosyn-
chronic P. aeruginosa infections, the composition of thethesis of alginate and LPS, and may facilitate clear-
O-antigen polysaccharide changes from a heteropolym-ance of the bacteria by the host immune system and
eric (B-band) to a homopolymeric (A-band) form. Al-increase the efficacy of conventional antibiotic treat-
though not fully understood, the conversion to A-bandment against chronic P. aeruginosa infections.
phenotype appears to be beneficial to the bacterium by
reducing its immunogenicity and sensitivity to certain
Introduction antibiotics [2]. LPS is the major antigen component of
immune complexes isolated from the sputum of CF pa-
Pseudomonas aeruginosa is a widespread Gram-nega- tients with chronic P. aeruginosa [5]. In addition, be-
tive bacterium, commonly found in fresh water and soil. cause of its ability to overstimulate the immune system,
It is also a deadly opportunistic human pathogen that the presence of LPS in the lungs likely contributes to
causes life-threatening infections in immunocomprom- the cycle of infection/inflammation that eventually leads
ised hosts, including cystic fibrosis (CF), burn, and che- to irreversible lung damage in the CF patient.
motherapy patients [1]. P. aeruginosa is a leading cause In P. aeruginosa, the biosynthetic pathways of algi-
of hospital-acquired infections, and one of the top three nate and LPS share several common steps (Figure 1).
pathogens responsible for sepsis by Gram-negative The algC gene is strategically placed in these pathways,
bacteria [2]. Chronic P. aeruginosa infections are notori- leading to the production of the key intermediate GDP-
ously difficult to treat due to the organism’s ability to mannose that is necessary for both alginate and LPS
grow in a biofilm and become resistant to a wide variety A-band polysaccharide biosynthesis. AlgC encodes the
of antibiotic agents. enzyme PMM/PGM, which has both phosphomannomu-
CF patients are highly susceptible to lung infections tase and phosphoglucomutase activities. It was origi-
by P. aeruginosa, presumably due to the unique environ- nally identified by complementation as essential for algi-
ment of the CF lung. The CF genetic defect impairs the nate biosynthesis [6] where it catalyzes the conversion
ability of patients to clear bacteria from their airways of mannose 6-phosphate to mannose 1-phosphate.
and may also decrease the effectiveness of the immune More recently, it was found that PMM/PGM has an addi-
response. Many CF patients have a history of coloniza- tional role in LPS biosynthesis, converting glucose
tion by P. aeruginosa that spans more than a decade, 6-phosphate to glucose 1-phosphate in the production
and the establishment of chronic lung infections by P. of sugar precursors destined for the core region of LPS
aeruginosa is correlated with a poor prognosis for these [7, 8]. Homologs of several enzymes in the LPS and
patients. Despite the development of new anti-infective alginate biosynthetic pathways have been identified in
agents and intensive drug therapy, these infections are
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phosphorylated state. The mechanism of PMM/PGM is
believed to closely parallel that of a related protein:
phosphoglucomutase (PGM) from rabbit muscle. PMM/
PGM shows limited but significant sequence identity to
rabbit PGM that has been extensively characterized by
Ray and colleagues ([13] and references therein). After
the initial transfer of the phosphoryl group from the en-
zyme, the reaction of both enzymes is believed to pro-
ceed via diffusional reorientation of the bis-phosphory-
lated intermediate in the active site, followed by a
second phosphoryl transfer to regenerate the phosphor-
ylated form of the enzyme.
The dual roles of PMM/PGM in alginate and LPS bio-
synthesis of P. aeruginosa make the enzyme an attrac-
tive target for inhibitor design. However, little is known
about the details of the enzymatic mechanism or protein
structure that will aid such design efforts. To this end,
we have initiated detailed mechanistic and structural
studies of the protein, and report here the determination
of the three-dimensional structure of the wild-type pro-
tein and an active site mutant of the enzyme.
Results
Structure Determination and Description
The crystal structure of PMM/PGM from P. aeruginosa
was determined by MAD phasing using crystals of theFigure 1. A Schematic Illustrating the Role of PMM/PGM from P.
selenomethionine-substituted protein and has been re-aeruginosa in the Overlapping Biosynthetic Pathways of Alginate
fined to 2.2 A˚. This model was used to solve the structureand LPS
of an active site mutant (S108A) of the enzyme thatThe enzyme catalyzes the conversion of mannose 6-phosphate to
mannose 1-phosphate in the second step in the biosynthesis of has been refined to 1.75 A˚ resolution (see Experimental
alginate, and also in the production of A-band polysaccharide of Procedures and Tables 1 and 2). Comparison of the
LPS. A similar conversion of glucose 6-phosphate to glucose 1-phos- selenomethionine-substituted wild-type enzyme struc-
phate is also catalyzed by PMM/PGM and produces sugars for the
ture with that of the S108A mutant shows that there arecore region of LPS.
no significant differences attributable to the substitution
of selenomethionine for methionine and that the struc-
ture of the S108A mutant is very similar to the wild-typeP. aeruginosa [9], and therefore these steps may be
difficult targets for inhibition. However, there is no protein with the exception of the mutated residue. In
the following sections, we describe features of the wild-known homolog of PMM/PGM. Thus, this enzyme ap-
pears to play a key role in the production of both of type protein, and indicate differences with the S108A
mutant when relevant.these bacterial virulence factors in P. aeruginosa.
The relevance of PMM/PGM to the pathogenesis of PMM/PGM contains four domains (Figure 2A) of ap-
proximately equal size, arranged in an overall “heart”P. aeruginosa infections has been shown using an algC
knockout strain. Mouse models of infection show this shape. Each domain contains bothhelices and sheet.
Domains 1–3 share a common topological core: a mixedstrain is less virulent than that of the wild-type bacteria
[10, 11]. In addition, algC is upregulated as a response / structure consisting of a four-stranded sheet sand-
wiched between two  helices (Figures 2B and 2C). Theto bacterial attachment to a surface during biofilm for-
mation [12]. Cells unable to upregulate algC are less strands in the  sheet are in the order 2134, with strand
4 antiparallel to the rest. Although they are structurallyable to remain attached to a glass surface in in vitro
biofilm models. While not an essential enzyme for the similar, the amino acid relationship between the three
domains is undetectable by standard sequence align-bacteria, effective inhibition of PMM/PGM may be ex-
pected to interfere with alginate and LPS production, ment methods: the amino acid identity between any
two superimposed pairs is less than 20% (based onand impair biofilm maintenance, thereby making the
bacteria more susceptible to the host immune response structural superposition with MAPS [14] using the C
pairs automatically aligned by this program). Each do-and traditional antibiotic therapy.
PMM/PGM is part of a family of phosphohexomutases main has several insertions relative to the common core:
domain 1 has two additional  helices and three extrathat catalyze intramolecular phosphoryl transfer utilizing
a phosphoserine residue [4]. The protein has 463 resi-  strands; domain 2 has one extra  helix; and domain
3 has three additional  helices and one extra  strand.dues and exists as a monomer in solution. The active
form of the enzyme is phosphorylated at Ser108 and Despite the common topology and three-dimensional
fold of domains 1–3, the PMM/PGM structure does notrequires Mg2 for full activity. The activator glucose 1,6-
bis-phosphate is required to maintain the enzyme in the contain a pseudo 3-fold axis; however, an approximate
Crystal Structure of PMM/PGM
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Table 1. Data Collection Statistics
Crystal MAD S108A
1 2 3 4
Wavelength (A˚) 0.979151 0.979432 0.971480 0.986945 1.54
Resolution (A˚) 2.2 2.2 2.2 2.2 1.75
Rsym (%) 7.1 (33.3) 6.4 (28.8) 7.1 (33.2) 6.4 (32.7) 5.3 (36.3)
Ranom (%) 5.4 4.4 5.7 4.3 —
Unique reflections 24,319 24,290 24,090 23,990 49,105
Observed reflections 185,144 192,257 95,570 89.620 240,203
Completeness (%) 96.5 (98.7) 96.7 (98.6) 96.3 (98.0) 95.0 (97.1) 97.4 (98.8)
I/(I) 27.8 (5.8) 30.0 (7.2) 19.7 (3.9) 20.1 (4.0) 28.5 (2.3)
Numbers in parentheses refer to statistics for the highest resolution shell.
2-fold axis (176 rotation) is found between domains 1 The crystal structure shows that the active site of
PMM/PGM is found in the center of the protein, in aand 3. While it appears the first three domains of the
deep cleft formed by atoms in 67 residues distributedprotein arose from an ancient gene duplication event,
across all four domains. The cleft has a solvent accessi-domain 4 is unrelated structurally to the others, and
ble surface area of approximately 1100 A˚2 in the wild-is a member of the TATA-box binding protein-like fold
type protein [18]. Topologically equivalent loops in do-superfamily [15]. It consists of a four-stranded antiparal-
mains 1–3 (between strands 3 and 4 of the conservedlel  sheet flanked by two  helices, and two short 
core) point toward the active site, clustering residuesstrands.
involved in enzyme activity/specificity (see followingThe four domains of PMM/PGM pack as a relatively
sections). Residues from domain 4 also contribute tocompact structure. The polypeptide proceeds through
the cleft and are primarily located on strands 3 and 4each domain sequentially, with only one chain crossing
of the antiparallel  sheet. Although the overall chargebetween domains. Extensive contact surface areas of
of the protein is negative (calculated pI  5.24), the993 and 1300 A˚2 (15% and 21% respectively, of their
active site has a net positive charge, as would be ex-total surface areas) are found between domain pairs
pected for binding of its anionic substrate and intermedi-1–2 and 2–3. Domains 1 and 3 also have a significant
ate (Figure 2D).interface area of 547 A˚2 despite the intervening domain
2. Domain 4 has less extensive interactions with the rest
Structural Relativesof the molecule: 660 A˚2 total shared surface area with
The overall fold of PMM/PGM is found in one otherdomain 3, involving only 11% of its total surface area.
protein of known structure—that of PGM from rabbitThe 3–4 domain interface also stands out for its high
muscle. This protein is involved in the synthesis andgap volume, a measure of the complementarity of the
breakdown of glycogen and is an essential enzyme ininteracting surfaces [16]. Its gap volume index [gap vol-
humans. Rabbit muscle PGM has been extensively char-ume (A˚3)/interface accessible surface area (A˚2)] is 2.39 A˚,
acterized, both mechanistically and structurally [13, 17,more than twice that of the other two consecutive do-
19, 20]. As its name implies, PGM is highly specific formain interfaces, and is similar to those typically found
glucose-based substrates, showing a 6000-fold prefer-in dimeric protein interfaces [16]. The low surface com-
ence for glucose over mannose in the biosynthetic direc-plementarity of this interface, combined with its rela-
tion of the reaction [21]. This contrasts with pseudomo-tively small surface area, leads us to suggest conforma-
nad PMM/PGM that shows equal preference fortional flexibility between domain 4 and the rest of the
glucose- and mannose-based substrates [22]. The twomolecule. Flexibility between domain 4 and the rest of
enzymes also have differing metal binding specificity:the protein has also been indicated for rabbit PGM [17].
both require Mg2 for maximum activity, but rabbit PGM
is also activated by Co2 and Ni2.
The relationship of the two proteins was originallyTable 2. Refinement Summary
shown by amino acid sequence comparisons that clearlyWild-Type S108A Mutant
identify the conservation of important functional ele-
Resolution (A˚) 2.2 1.75 ments, despite a relatively low overall sequence identity
Rcryst 23.4 16.9 (22%). A structural alignment of the two proteins (Figure
Rfree 27.6 19.6 3) shows that they share the same overall heart shapeRmsd bond distance (A˚) 0.015 0.017
and four-domain architecture. Since PGM has a total ofRmsd bond angle (deg) 1.6 1.6
561 residues, 98 more than PMM/PGM, it has severalTotal no. non-H atoms 3,565 3,893
Number of solvent molecules 166 435 additional secondary structural elements; these tend to
Avg. protein B-value (A˚2) 46.4 32.2 fall on the periphery of the molecule, distant from the
Avg. solvent B-value (A˚2) 45.2 46.6 active site. The two structures (3PMG and 1K35) can be
Heteroatoms P-Ser, Zn2 Tartrate, Zn2 aligned with a root-mean-square (rms) deviation of 1.8 A˚
Rcryst  |Fo 	 Fc|/|Fc| where Fo and Fc are observed and calculated for 312 C residues [14]. This alignment shows that criti-
structure factors, respectively. Rfree is the R factor calculated from cal residues in the active site are in very similar positions,
5% of the reflections not included in refinement. P-Ser is a phos- including the active site serine, metal binding loop, and
phorylated serine residue.
phosphate binding site (see following section).
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Figure 2. Structure, Topology, and Electrostatic Surface of PMM/PGM
(A) Ribbon diagram of PMM/PGM colored by domain. Domain 1 (residues 1–153) is shown in green, domain 2 (residues 154–256) in yellow,
domain 3 (residues 257–368) in red, and domain 4 (residues 369–463) in blue. Residues involved in enzyme activity/specificity are shown as
sticks and highlighted with numbered arrows: (1) active site phosphoserine (Ser108), (2) metal binding loop (Zn2 shown as magenta sphere),
(3) Ser327 in the sugar binding loop; (4) residue Arg421 in the distal phosphate binding site.
(B) Topology diagram of PMM/PGM, showing each domain in the same colors used in (A). Helices are indicated by rectangles and  strands
by arrows; strands that form a  sheet are shown adjacent to one another. In domains 1–3, the four  strands in the common topological
core are numbered, and the loop between strands 3 and 4 is marked with an asterisk. Helices and strands that are not part of the common
core are shown in lighter colors. The  helix preceding strand 1 of the common core is divergent in its three-dimensional orientation was
therefore not included as part of the motif.
(C) Superposition of C atoms in the common core regions of domains 1–3 using the same colors as in (A). The four-stranded  sheet is in
the center sandwiched between two conserved  helices. The side chains of residues on the loop between strand 3 and 4 are shown as a
stick models; residues outside of the core regions have been omitted for clarity. The rms deviation between core pairs is 1.39, 1.57, and
1.47 A˚2 for domains 1–2, 1–3, and 2–3 (for 46, 29, and 42 C pairs, respectively) [14].
(D) Electrostatic surface potential calculated by MOLMOL [45] of PMM/PGM showing the cluster of basic charge in the active site cleft. Red
indicates negative charge; blue indicates positive. Protein is shown in the same orientation as (A).
Multiple structures of PGM are available in the PDB, sequence homology of PMM/PGM with rabbit PGM is
relatively low, many residues involved in the active siteincluding four with various metal ions (3PMG, 1VKL,
1LXT, and 1JDY) and two in complex with an intermedi- are highly conserved, and these complexes can provide
approximate models for binding of substrate to PMM/ate or inhibitor (1C4G, 1C47). With the exception of
3PMG that has been refined to 2.4 A˚ [17], the resolution PGM. References to these PGM structures are included
in the following sections when relevant.of all of these structures is 2.7 A˚. The two PGM com-
plexes, although deposited, have not been described in
a publication. One of these is a complex with the reaction Details of Active Site
Sequence comparisons and biochemical and mutationalintermediate glucose 1, 6-bis-phosphate (G16P); the
other is a covalent complex with the inhibitor glucose analyses have indicated residues important for the activ-
ity and specificity of PMM/PGM [4]. These can be1-phosphate, 6-vanadate (G1P6V). Although the overall
Crystal Structure of PMM/PGM
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Figure 3. Superposition of PMM/PGM from
P. aeruginosa with PGM from Rabbit Muscle
PMM/PGM is shown in the same orientation
as in Figure 2A. A trace of the C atoms of
each protein is shown with PMM/PGM in red,
and PGM in blue. The Zn2 ion from PMM/
PGM is shown as a magenta sphere, and the
Mg2 ion from PGM is shown as a green
sphere.
grouped into four distinct regions of the protein: (1) the conformation is retained in the S108A mutant structure
where the backbone angles of Ala108 are φ  60 andactive site serine (residue 108) involved in phosphoryl
group transfer; (2) a metal binding loop (residues 242– 
  	115, despite the fact that it no longer acts as a
ligand for the metal.246) that chelates a Mg2 ion required for activity; (3)
a sugar binding loop (residues 324–328) predicted to Metal Binding Loop
In PMM/PGM, a bound Mg2 ion is required for full activ-contain residues that distinguish between related sugar
substrates; and (4) the distal phosphate binding site ity and presumably serves to activate the phosphate
group of Ser108 for transfer by stabilizing negative(containing Arg421) believed to interact with the bis-
phosphorylated reaction intermediate. Since the reac- charge on the phosphoryl group or leaving group during
catalysis. The role of the metal ion in activation has beention intermediate contains two phosphate groups (and
therefore the enzyme has two phosphate binding sites), extensively characterized for rabbit PGM [23]. In the
crystal structure of wild-type PMM/PGM, phosphoser-we will hereafter refer to them as either proximal (near
Ser108) or distal (opposite end of active site near ine 108 and the metal binding loop are in close proximity
to each other, with a terminal oxygen atom from theArg421). In the following section, we describe the struc-
tural elements of each of these regions in detail, and phosphorylated serine providing one ligand for the
bound metal ion (Figure 4B). Three other metal ligandsconclude with a description of the binding of a tartrate
molecule in the active site of the S108A mutant structure. come from the carboxylate side chains of aspartates
242, 244, and 246. The metal ion in the crystal structureActive Site Serine
PMM/PGM catalyzes reversible intramolecular phos- is believed to be Zn2, rather than Mg2 that is required
for enzymatic activity (see Experimental Procedures).phoryl transfer from the 1 to the 6 position of its sugar
substrates utilizing a phosphorylated serine residue. In the S108A mutant of PMM/PGM, the phosphoserine
residue is absent, and a new ligand replaces it in theSequence comparisons with rabbit PGM suggested
Ser108 as the site of phosphorylation, and mutagenesis crystal structure: an oxygen atom from the carboxylate
group of a tartrate molecule, presumably arising fromexperiments have confirmed its important role in enzyme
activity [22]. In the crystal structure of the wild-type the precipitant used for crystallization: 1.4 M Na, K tar-
trate. Ligand bond distances for the wild-type and mu-PMM/PGM, Ser108 appears to be fully phosphorylated
as judged by electron density maps (Figure 4A); the tant structures are given in Table 3 and are consistent
with those seen in other Zn2 binding sites [24, 25]. Inphosphorylation state of the enzyme is supported by
mass spectrometry (data not shown). Two oxygens of both structures, the metal-ligand geometry is approxi-
mately tetrahedral.the phosphate group interact with other residues in the
active site: one serves as a ligand to the bound metal Sugar Binding Loop
PMM/PGM belongs to a subclass of phosphohexomu-ion (see next section) and another forms a hydrogen
bond with the side chain of the neighboring residue, tases that are primarily found in bacteria and often func-
tion in the synthesis of exopolysaccharides. This sub-His109. The loop containing Ser108 is quite well defined
in electron density maps. However, the backbone dihe- class demonstrates dual substrate specificity for
glucose and mannose, which are epimers at the C2dral angles of this residue fall in the disallowed region
of a Ramachandran plot (φ  50, 
  	115) defining position of the sugar ring. They have a conserved se-
quence motif in domain 3, 324-GEMS(G/A)-328, whicha rare type II -turn. Presumably this unusual conforma-
tion reflects a functional requirement for maintaining this has been postulated to act as a sugar binding loop and
determine the specificity (or lack thereof) for glucoseresidue in a specific orientation for enzyme activity. This
Structure
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Table 3. Geometry of Metal Binding Loop
Bond lengths to Zn2 in A˚:
Residue Type & No. Atom Type Wild-Type S108A Mutant
D242 O 1.79 1.89
D246 O 2.22 2.03
D248 O 2.02 1.89
Phosphoserine 108 O 2.06 —
Tartrate O — 1.84
versus mannose [4]. In the PMM/PGM structure, the
loop containing these residues is solvent accessible and
forms part of the active site cleft (Figure 4B). The side
chains of Glu325, Ser327, and His329, another highly
conserved residue, point toward Ser108 and the metal
binding loop, and should be available to interact with
bound substrates.
The sugar binding loop in domain 3 has also been
called the “specificity loop” [17] and was proposed to
determine the relative binding affinity of glucose versus
mannose for members of the phosphohexomutase fam-
ily. Enzymes with a strong preference for glucose, like
rabbit PGM, have a different sequence signature, 374-
GEESFG-379, on the equivalent loop in domain 3 [4].
However, comparison of the PMM/PGM structure with
that of PGM and analysis of the residues in PGM com-
plexes that interact with bound sugars, suggest that this
loop alone is probably insufficient for determining the
sugar binding affinities. In the rabbit PGM complexes,
residues from the sugar binding loop do indeed contact
the bound sugars: the side chains of Glu375 and Ser377
(analogous to Glu325 and Ser327 in PMM/PGM) are
within hydrogen bonding distance of O3 on the glucose
ring. However, no contacts are apparent between resi-
dues on the sugar binding loop and O2, the site at which
mannose and glucose are epimers. In the PGM complex
with G16P, a residue (Thr356) from a different loop in
domain 3 does form a hydrogen bond with O2 of the
bound sugar. However, since PMM/PGM has an identi-
cal residue at the equivalent position (Thr306), the struc-
tural determinants for the high specificity of PGM for
glucose-based substrates remain unclear.
Distal Phosphate Binding Site
After phosphoryl transfer from Ser108, the active site of
PMM/PGM must temporarily accommodate an interme-
diate with two phosphate groups at positions 1 and 6
of the sugar. A cluster of positively charged, conserved
residues is found at the end of the active site distal to
Ser108. These include Arg421 and Arg432 from domain
4, and also Lys285 from domain 3. Mutagenesis data
for one of these residues, Arg421, reveals a crucial role in
enzyme activity. The mutant strain 8858 of P. aeruginosa
was isolated as deficient in alginate production [6]. This
strain shows a single mutation in the algC gene, chang-
Figure 4. Details of the PMM/PGM Active Site
(A) Electron density map from the MAD data set using phases calcu-
lated by SHARP showing the active site of PMM/PGM in the vicinity
of phosphoserine 108, and the metal binding loop (residues 242–246) dues in domains 1–4 are colored as in Figure 2A.
with bound Zn2 ion (magenta sphere). Protein residues are shown (C) Schematic illustrating binding of () tartrate in the active site of
as ball-and-stick model with yellow for carbon, red for oxygen, blue the S108A PMM/PGM mutant structure. Domains are colored as in
for nitrogen, and orange for phosphorus atoms. The electron density Figure 2A. Dashed lines indicate potential hydrogen bonds or salt
is contoured at 1.0  and is shown in cyan. bridges between the tartrate and protein residues. Except for the
(B) Close-up view of residues in the active site of PMM/PGM, illus- tartrate-Zn interaction (see Table 3), contact distances range from
trating the four regions involved in enzyme activity/specificity. Resi- 2.8–3.1 A˚ and are between hydrogen-bonding partners.
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ing residue 421 of PMM/PGM from an arginine to a may make some interactions analogous to those with
its glucose or mannose-based substrates. In the PGMcysteine. Kinetic data (P.A.T., unpublished data) shows
that the R421C mutant of PMM/PGM has a Km for glu- complexes, the residues analogous to Lys118 and
Arg247 (Lys129 and Arg292) both contact the proximalcose 1-phosphate of 20 M, several-fold higher than
the Km of the wild-type enzyme. However, the kinetic phosphate/vanadate group of the bound intermediate/
inhibitor. An additional residue in PGM, Lys388, is in aparameters V/K and Vmax are dramatically reduced, sug-
gesting that the primary effect of the mutation is not on spatially similar position to His329 in PMM/PGM, and
also contacts the proximal phosphate/vanadate group.substrate binding.
In the crystal structure of PMM/PGM, Arg421 is14 A˚ His308 of PMM/PGM, however, is most closely aligned
with a partially buried tryptophan in rabbit PGM thataway from Ser108 and the metal binding loop. The two
phosphate groups on G16P are separated by approxi- makes no contacts with bound sugars.
Therefore, with the exception of His308, residues ofmately 10 A˚. Thus, a small conformational change, such
as a rotation of domain 4, could position this residue PMM/PGM involved in binding tartrate seem to be equiv-
alent to a subset of those used by PGM to bind itsfor binding of the intermediate. The important role of
Arg421 is supported by its high sequence conserva- physiologically relevant ligands.
tion with other phosphohexomutases and also by struc-
tural data on rabbit PGM. In the PGM complex with
Implications for Enzyme MechanismG16P, the analogous residue (Arg502) is 3.4 A˚ from the
In alginate and LPS biosynthesis, PMM/PGM catalyzes1-phosphate group of the sugar. However, in the PGM
the transfer of a phosphoryl group from the 6 to the 1complex with inhibitor G1V6P, Arg514 (analogous to
position of mannose or glucose-based substrates (Fig-Arg432 in PMM/PGM) appears to make the best interac-
ure 5). Based on the well-studied mechanism of rabbittion with this phosphate group (2.4 A˚) with a second
PGM, the reaction of PMM/PGM has been proposedcontact mediated by Thr18 from domain 1. Therefore,
to proceed through the following steps: (1) binding ofit seems likely that other residues in PMM/PGM, like
mannose or glucose 6-phosphate to the active (phos-Arg432 and possibly residues in other domains, may
phorylated) state of the enzyme; (2) transfer of the en-also be important in forming the distal phosphate bind-
zyme phosphoryl group from Ser108 to the 1 positioning site.
of the sugar substrate, creating a bis-phosphorylatedBinding of Tartrate to S108A Mutant
intermediate; (3) diffusional reorientation of the interme-Attempts to observe a PMM/PGM complex with sub-
diate in the active site placing the phosphoryl group atstrate or intermediates by X-ray crystallography have
position 6 near the active site serine; and (4) regenerationnot yet been successful, possibly due to the high con-
of the phospho-enzyme by transfer of the phosphorylcentration (1 M) of Na, K-tartrate necessary for crystal-
group at position 6 of the sugar back to Ser108. Salientlization. However, in the S108A mutant structure, a tar-
features inherent to this mechanism include a key roletrate molecule binds in the active site, providing the
for Ser108 in phosphoryl transfer, and as yet unidentifiedfourth ligand for the bound metal ion in lieu of phospho-
residues to assist in general acid/base catalysis. In addi-serine 108. Tartrate is a four-carbon carbohydrate, with
tion, the mechanism implies significant reorientation ofcarboxylate groups at C1 and C4, and hydroxyl groups
the intermediate in the active site without allowing itsat C2 and C3. While its presence in our structure was
release into solution, as well as specific binding of thefortuitous (due to its role as precipitant in crystallization),
same substrate in two distinct orientations. Finally, thetartrate may serve as a useful scaffold for future efforts
enzyme must be able to accommodate both glucoseat inhibitor design.
and mannose-based substrates. The implications of theMultiple interactions are found between the S108A
crystal structure for these issues are discussed below.mutant enzyme and the bound tartrate (Figure 4C). In
The proposed mechanism for PMM/PGM predicts athe absence of phosphoserine 108, an oxygen from a
critical role for Ser108 in phosphoryl transfer during ca-carboxylate group of tartrate provides the fourth ligand
talysis. Indeed, the presence of an active site serine isfor the bound metal ion, completing its tetrahedral coor-
strongly conserved in members of the phosphohexomu-dination sphere. In total, five of the six tartrate oxygens
tase family, including rabbit PGM, and the crystal struc-appear to interact with the protein. Direct hydrogen
ture of the wild-type protein confirms that this residuebonds to tartrate are mediated by the side chains of
is in fact phosphorylated. Therefore, it was surprisingfour residues: Lys118, Arg247, His 308, and His 329.
to find that site-directed mutants of this residue (S108AAn additional residue, Asp18, is involved in a water-
and S108V) retain significant catalytic activity (Vmax andmediated contact. Although PMM/PGM was crystallized
V/K 5% of wild-type) [22]. Although diminished, thisin a mixture of (/	) tartrate, only the () stereoisomer,
activity is substantially more than that expected afterin the energetically favorable trans conformation, is
removal of a catalytically “required” residue. Further-found in the active site, indicating some specificity of
more, like the wild-type enzyme, the S108A mutantbinding. Modeling of the (	) stereoisomer indicates that
shows substrate inhibition and requires G16P as an acti-while it could still coordinate the metal ion and avoid
vator, implying that a phosphorylated residue on thesteric conflicts with protein residues, it would be unable
enzyme is still involved in activity. The crystal structureto make the additional contacts with Lys118 and His329,
suggests that the residue adjacent to Ser108, His109,although it could potentially pick up a new contact with
may be a candidate for an alternative phosphorylationthe side chain of His109.
site. In the wild-type structure, the N of His109 is 3.0 A˚Although tartrate is smaller than the six-carbon sub-
strates of the enzyme, and linear rather than cyclic, it from the O1P of phosphoserine 108. Manual rotation of
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Figure 5. Schematic of the Proposed Mecha-
nism for the Conversion of Mannose-1 Phos-
phate to Mannose-6 Phosphate by PMM/
PGM
Phosphate groups are indicated by “P”, gen-
eral base by “B”, and general acid by “HA”.
The reaction begins with binding of man-
nose-1 phosphate to the phosphorylated en-
zyme. A general base initiates transfer of the
phosphoryl group from Ser108 to the sub-
strate, through abstraction of a proton from
the 6-hydroxyl group of the sugar. A general
acid facilitates phosphoryl transfer to the
sugar by protonating the hydroxyl oxygen of
Ser108. The bis-phosphorylated intermediate
is believed to reorient (indicated by large arrow) in the active site allowing transfer of the phosphoryl group from position 1 of the sugar back
to Ser108. Candidate residues for the role of general acid and base are discussed in the text.
this side chain can bring the N of His109 to within 1.2 A˚ of the phosphate group of Ser108. A second possibility
for the general acid is Lys118, also a highly conservedof the O1P atom of phosphoserine and to within 3.0 A˚ of
the bound Zn2 ion. Thus, it seems fairly small structural residue. In the wild-type structure of PMM/PGM, the N
of Lys118 is 2.9 A˚ from 03P of the phosphoserine, andchanges, like side chain rotation or a minor shift of the
protein backbone, could position His109 for a role in 3.1 A˚ from O2P. In both the wild-type and mutant PMM/
PGM structures, the Lys118 side chain appears to becatalysis. BLAST [26] searches of GenBank reveal that
a related PMM/PGM from Xylella fastidiosa (44% identi- firmly anchored in the active site, making potential addi-
tional contacts with nonliganding side chain oxygens ofcal to the P. aeruginosa enzyme) completely lacks the
conserved active site serine; it is replaced by a glycine. Asp244 and Asp246 in the metal binding loop. Site-
directed mutagenesis supports involvement of residueHowever, this protein retains a histidine at the position
equivalent to 109, and also has additional histidines at 109 in catalysis: an H109Q mutant shows diminished
activity; characterization of a Lys118 mutant is under-positions 110 and 112 (residue numbers refer to the P.
aeruginosa enzyme). way (P.A.T., unpublished data).
During catalysis, the phosphoryl group on Ser108 isThe structure of PMM/PGM provides clues about
other residues important for activity. The proposed transferred to the substrate, and a second phosphoryl
group, 10 A˚ away, is transferred back to the samemechanism for the enzyme specifies a role for a general
base in initiating transfer of the phosphoryl group from serine residue. This implies significant movement on the
part of either the enzyme or the intermediate. NuclearSer108 to the substrate, through abstraction of a proton
from the 6-hydroxyl group of the sugar. Since no direct magnetic resonance studies of rabbit PGM [27] support
the latter possibility: reorientation of the bis-phosphory-structural information for a substrate or inhibitor is yet
available, we have identified possible candidates based lated reaction intermediate in the active site. In order
to exchange the positions of the 1- and 6-phosphateon their location in the active site and proximity to the
bound intermediate/inhibitor in superimposed PGM groups, a 180 rotation about an axis defined by O3 and
C5 of the intermediate is required. In the PGM com-complexes. Two residues in PMM/PGM stand out as
possible candidates for this role: His308 and His329. As plexes, it is not possible to perform this rotation without
causing significant steric clashes in the active site.noted previously, both of these residues are in the active
site cleft and interact with the bound tartrate molecule Therefore, it appears likely that the intermediate must
first dissociate from its high-affinity binding site deepin the S108A mutant structure. In the PGM complexes,
the N of Lys388 (analogous to His329) is 3.2 A˚ from in the active site, diffuse into the larger active site cleft,
rotate 180, and then rebind in the opposite orientation.O6. Without a bound substrate or intermediate in the
active site, it is impossible to precisely define the posi- This presents an unusual challenge for the enzyme,
which must release and rebind its intermediate withouttion of O6, and other residues in its likely vicinity include
Arg20 and Arg247. They may also be candidates for the losing it to the bulk solution, and may explain the pres-
ence of such a large active site cleft in the enzyme,general base.
Following abstraction of its proton, the O6 of man- despite the small size of its substrates. It also seems
likely that conformational flexibility between domain 4nose/glucose performs a nucleophilic attack on phos-
phoserine 108, catalyzing transfer of the phosphoryl and the rest of the protein may facilitate this process,
with domain 4 potentially moving to aid reorientation orgroup to the sugar. This process is aided by a general
acid on the protein that donates a proton to the side prevent dissociation of the intermediate during cataly-
sis. Changes in the volume and surface area of the activechain oxygen of Ser108. We have identified two residues
that are strong candidates for the general acid: His109 site cleft are evident when comparing PGM structures,
some of which arise from a rotation of domain 4 relativeand Lys118. In the structure of native PMM/PGM, both
of these residues appear to be well positioned to act as to the rest of the protein ([17] and L.J.B., unpublished
data).proton donors. Although His109 is immediately adjacent
to Ser108, the geometry of the unusual type II turn in It has been proposed [20] that electrostatic interac-
tions between the positively charged active site and thethis loop allows its N to be positioned 3.0 A˚ from O1P
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anionic substrate/intermediates of PGM may provide mannose stereochemistry should be effectively ex-
cluded from binding to PGM. In addition, although thesufficient nondirectional binding energy to allow the dra-
matic reorientation of the intermediate without dissocia- enzymes are clearly related, their overall sequence iden-
tity is rather low, so there are many differences in resi-tion from the active site. It seems reasonable that the
bis-phosphorylated intermediate, which is tetra-anionic, dues in nonconserved areas of the active site. Some of
these have been noted in the discussion (e.g., His308should be more tightly associated with the positively
charged active site, than the di-anionic substrates. How- versus Trp358). It should be possible to design inhibitors
that interact with or are excluded by residues that differever, in the proposed mechanism for PGM and PMM/
PGM, it is this highly charged intermediate, rather than between the two proteins. Such a strategy has been
successful with more closely related proteins, includingthe substrate, that must dissociate and reorient in the
active site, which is seemingly in conflict with its higher the isoforms of human cyclooxygenase [28]. As in that
case, since the structures of both enzymes are nowbinding affinity. Therefore, the relative roles of electro-
static attraction versus other factors, like potential con- known, these and other specific design questions can
be addressed in a structural context at atomic detail.formational changes in the enzyme, during catalysis re-
main to be elucidated. Future studies that will facilitate inhibitor design in-
clude continued characterization of enzyme mechanism
and additional site-directed mutagenesis to confirm our
Implications for Inhibitor Design proposed role for many residues in activity. A direct
The key role of PMM/PGM in the biosynthesis of viru- comparison of high-resolution structures of PMM/PGM
lence factors from P. aeruginosa makes it an attractive and PGM in complex with bound substrates/inhibitors
target for inhibitor design. The underlying function of should be extremely useful, especially in addressing
both alginate and LPS is to form a protective barrier questions about enzyme specificity and potential con-
around the bacterium. Disruption of this barrier, or per- formational changes in the protein during catalysis.
haps even small changes in its permeability or stability, Characterization of PMM/PGM complexes has been re-
may increase the effectiveness of the host immune re- calcitrant to date, but alternative approaches to stable
sponse and conventional antibiotic therapy. This would complex formation, including the formation of covalent
be of great benefit to CF patients and others who are adducts, are under investigation. Eventually, this work
colonized by antibiotic resistant strains of P. aeruginosa. should provide a better understanding of the enzyme’s
In addition, since phosphohexomutases with dual sub- ability to efficiently catalyze a reaction with two different
strate specificity are found primarily in bacteria, inhibi- substrates, accommodate a dramatic rotation of the
tors developed for PMM/PGM in P. aeruginosa may reaction intermediate in the active site, and bind the
serve as models for fighting infections by other organ- intermediate with high affinity in two different orienta-
isms such as Vibrio cholerae, Klebsiella pneumoniae, tions.
and Mycobacterium tuberculosis.
Several features of PMM/PGM should facilitate design
of inhibitors. First, the enzyme’s natural substrates are Biological Implications
small molecules with well-studied chemistry that should
lend themselves to the design and synthesis of related Enzymes with dual specificity for mannose- and glu-
cose-based substrates form a subset of the phospho-molecules that can function as inhibitors or inactivators.
The structure of the S108A PMM/PGM mutant reveals hexomutase family. PMM/PGM enzymes are found in
many different bacteria, and often play a role in thethat even simpler carbohydrates like tartrate can effec-
tively utilize residues in the active site for binding and synthesis of bacterial exoproducts. PMM/PGM from P.
aeruginosa is the first representative of this enzyme sub-might serve as a scaffold for design of more potent
inhibitors. Second, detailed mechanistic studies of the family to be structurally characterized, and, as such, it
provides a high quality model for other mutases withenzyme mechanism are underway [22] and several mole-
cules with inhibitory activity (e.g., xylose 1-phosphate, dual sugar specificity.
In the case of P. aeruginosa, an opportunistic human1-deoxyglucose 6-phosphate) have already been char-
acterized ([22] and P.A.T., unpublished data). Finally, a pathogen, PMM/PGM is an important enzyme in the
biosynthesis of both alginate and LPS, two moleculeshigh-resolution view of the active site is now available,
providing detailed three-dimensional information on that affect the pathogenicity of the organism. Inhibition
of its biosynthetic roles may help make the bacteriaresidues that might be utilized for inhibitor binding.
The potential clinical utility of PMM/PGM inhibitors is more susceptible to the host immune system and con-
ventional antibiotic treatment, providing a new approachcomplicated by the presence of the essential eukaryotic
PGM homolog that is found in many tissues and organs. to treating CF and other patients with chronic P. aerugi-
nosa infections.In particular, the similarity of the active sites of these
two proteins provides a challenging, but hopefully not The high-resolution structure of PMM/PGM from P.
aeruginosa provides a detailed view of the enzyme’sinsurmountable, hurdle for inhibitor design. Several im-
portant differences between the two enzymes might be active site and suggests residues involved in catalysis.
The structure of an active site mutant of PMM/PGMexploited to overcome this challenge. PMM/PGM owes
its dual substrate activity for glucose and mannose to reveals multiple interactions with a bound tartrate mole-
cule that may serve as a useful scaffold for future effortsa lack of specificity for epimers at the C2 position of
the sugar. PGM, on the other hand, is highly specific at inhibitor design. Together with the mechanistic and
mutagenesis studies already underway, these struc-for binding of glucose. Therefore, inhibitors based on
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following residues was also not well defined and they have beentures provide new insights into the details of the enzy-
truncated to alanine: K5, Q78, E124, E129, E136, E139, S145, L156,matic reaction and set the stage for structure-based
E205, K219, E221, K224, Q357, and E438. Refinement statistics areinhibitor design.
shown in Table 2.
The metal ion in both PMM/PGM structures has been modeled
Experimental Procedures as Zn2 ion. Initial attempts to use Mg2 in the wild-type model
resulted in a 10  positive density peak at the position of the metal
Crystallization and Data Collection in Fo 	 Fc maps. Subsequent metal analysis by inductively coupled
Purification and crystallization of native and SeMet PMM/PGM were argon plasma emission spectroscopy (Chemical Analysis Labora-
carried out as previously described [29]. A four wavelength MAD tory, University of Georgia) of both the protein sample and of the
data set and 1.75 A˚ native data set were collected at	180C at beam tartrate solution used for crystallization revealed numerous contami-
line X8C at the National Synchrotron Light Source of Brookhaven nating ions, including Ca2, Zn2 and others at lower levels (data
National Laboratory. Statistics for the X-ray diffraction data are pre- not shown). Based on the known high-affinity binding of Zn2 to
sented in Table 1. A mutant of PMM/PGM (S108A) was crystallized rabbit PGM [38], and evaluation of the unrestrained metal-ligand
in conditions similar to the wild-type protein [29] and in the same bond lengths and geometry, Zn2 was selected for the identity of
space group (P212121), but with slightly different cell constants (a  the ion; this choice eliminated the positive density peak in Fo 	 Fc
71.1, b 71.3, c 94.4 A˚). Macroseeding was used to produce large maps on the site of the ion, and refined to a reasonable B-factor
single crystals for data collection. The S108A crystals diffracted to with full occupancy in both structures.
high resolution and a complete data set was collected using a Rigaku Both the wild-type and S108A enzyme structures have good ge-
rotating anode generator and R-AXIS IV area detector (Table 1). ometry, with 89% and 92.3%, respectively, of their residues lying
in the most favored regions of the Ramachandran plot [39]. The
models were also evaluated by ERRAT [40], 3D-1D profiles [41],Structure Solution and Refinement
SFCHECK [42], and WHAT_CHECK [43]. Figures were prepared withThe eight SeMet sites in the PMM/PGM monomer were located and
Molscript [44], MOLMOL [45], Bobscript [46], and Raster3D [47].refined using the program SOLVE [30]. Final Z score and figure of
merit were 56.0 and 0.53, respectively. Density modification of
Acknowledgmentsphases from SOLVE was performed with DM [31] yielding good-
quality electron density maps (fom  0.79). Improved maps were
We acknowledge Leon Flaks and the staff of beam line X8C of theobtained from the program SHARP [32] by refining the SeMet sites
National Synchrotron Light Source of Brookhaven National Labora-obtained from SOLVE followed by density modification with SOLO-
tory for synchrotron time and technical expertise. This work wasMON [33] using 46% solvent content. These maps revealed the
supported by NIH grant GM59653 and by a University of Missourilocation of several surface exposed loops that were absent in the
Research Board grant. We thank Melissa Myers for assistance withSOLVE/DM maps. The model was built interactively using O [34] in
protein purification. We are grateful to John Burgner for alerting uscombination with iterative cycles of simulated annealing and posi-
to the high affinity binding of rabbit PGM to Zn2.tional refinement, initially with CNS [35], and in the final stages with
REFMAC 5.0 [36] with individual, restrained B-factors. Progress was
Received: October 3, 2001monitored by use of Rfree and 5% of the data were set aside for
Revised: December 12, 2001cross-validation before refinement. Water molecules were placed
Accepted: December 17, 2001automatically by WATPEAK [37] in peaks greater than 3.0  in Fo 	
Fc maps and within hydrogen bonding distance to nitrogen or oxygen
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